brimonidine + corticosteroid

Brimonidine + corticosteroid is a combination drug consisting of **brimonidine**, an α2-adrenergic agonist, and a **corticosteroid** (various possible corticosteroids such as prednisolone or dexamethasone, which are synthetic glucocorticoids)[3]. Brimonidine reduces intraocular pressure by decreasing aqueous humor production and increasing uveoscleral outflow, commonly used in glaucoma and ocular hypertension[3]. The corticosteroid component exerts potent anti-inflammatory effects by suppressing multiple inflammatory pathways and cytokines, commonly used to reduce ocular inflammation or treat related conditions. This combination may be considered to both lower intraocular pressure and manage inflammation concurrently, especially in complex ophthalmic conditions. No uniquely branded or standardized formulation of brimonidine + corticosteroid is currently identified in the major literature or regulatory records, but such combinations may be compounded or used off-label in specific clinical scenarios.